arrow
A

Amy C Sherman

Brigham and Women's Hospital
H指数:23
被引数:2,948

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Demographic, Clinical, and Mycologic Differences Between Invasive Fungal Sinusitis and Pneumonia in Hematologic Malignancy

血液恶性肿瘤患者侵袭性真菌性鼻窦炎与肺炎在人口统计学、临床及真菌学方面的差异

2026-09-260
OA
Reactogenicity and Immunogenicity of RSV Vaccines in Immunocompromised Individuals With Hematological Malignancies

造血系统恶性肿瘤免疫受损个体中RSV疫苗的反应原性和免疫原性

2026-09-200
OAAI
Safety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomised, placebo-controlled trial

PanChol单剂量口服减毒霍乱疫苗的安全性与免疫原性:一项1a期、双盲、随机、安慰剂对照试验的结果

2026-01-070
OAAI
Evaluation of the safety and immunogenicity of two fractional intradermal regimens of MVA-BN compared to standard dose vaccination

评估两种分数剂量皮内接种MVA-BN方案与标准剂量疫苗接种的安全性和免疫原性比较

Vaccine
IF3.5
2025-11-290
PRE
Protracted SARS-CoV-2 Infection in B-cell Depleted Patients: Immunologic and Viral Characteristics and Response to Dual and Extended Antiviral Therapy

B细胞耗竭患者中慢性SARS-CoV-2感染:免疫学及病毒学特征以及对联合和延长抗病毒治疗的反应

2025-09-014
PRE
Computationally designed proteins mimic antibody immune evasion in viral evolution

计算设计的蛋白质模拟病毒进化中的抗体免疫逃逸

Immunity
IF26.3
2025-05-080
OA
Comparative Outcomes of Babesiosis in Immunocompromised and Nonimmunocompromised Hosts: A Multicenter Cohort Study
2025-01-280
PRE
Coronavirus Disease 2019 Vaccine Efficacy in Participants With Weakened Immune Systems From 4 Randomized controlled Trials
2024-04-101
PRE
A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults

一项2期临床试验,用于评估在健康美国成年人中使用和不使用AS03佐剂的2013年和2017 A(H7N9) 灭活流感病毒疫苗的安全性,反应原性和免疫原性

2024-03-274
PRE
Neuroinvasive Bacillus cereus Infection in Immunocompromised Hosts: Epidemiologic Investigation of 5 Patients With Acute Myeloid Leukemia
2024-01-252
OAAI
Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial
2023-08-2819
OAAI
Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Immunogenicity among Chimeric Antigen Receptor T Cell Therapy Recipients

嵌合抗原受体T细胞治疗受者的新型冠状病毒疫苗免疫原性

2023-06-0111
OAAI